Discover NUCALA (mepolizumab), an add-on maintenance treatment for patients 6+ with severe eosinophilic asthma, through efficacy data, patient profiles, and more.
add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus. add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRS...
With proven efficacy, established safety, and approvals across 4 indications—make NUCALA your first-choice biologic *IQVIA National Prescription Audit from January 2023 to December 2023 for all indications combined.FOR AGES 6+ NUCALA FOR SEVERE EOSINOPHILIC ASTHMA (SEA) GO TO NUCALA IN SEA FOR ...
VIEW NUCALA EFFICACY INDICATIONS NUCALA is indicated for the: add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus. ...
add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus. add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwN...
Hear from a peer NUCALA efficacy & safety in SEA | 15:58 An expert in pulmonology and critical care medicine describes how NUCALA can help patients with severe eosinophilic asthma (SEA), including an overview of safety and efficacy data....
11 years compared with adults and adolescents. The safety profile and pharmacodynamic response observed in this trial for children aged 6 to 11 years were similar to that seen in adults and adolescents. The safety and efficacy in pediatric patients aged younger than 6 years with severe asthma hav...
The safety and efficacy of Nucala in pediatric patients aged younger than 6 years with severe asthma have not been established. The safety and efficacy of Nucala in patients aged younger than 18 years with eosinophilic granulomatosis with polyangiitis (EGPA) have not been established. ...
In a clinical trial in patients with EGPA receiving 300 mg of Nucala, no additional adverse reactions were identified to those reported in severe asthma clinical trials. Injection site reactions (eg, pain, erythema, swelling) occurred in 15% of subjects treated with...
Find real world data from NUCALA (mepolizumab) clinical trials on exacerbation reduction in severe eosinophilic asthma patients.